Novartis Kisqali receives FDA approval for HR+ / HER2- metastatic breast cancer
Swiss-based healthcare company Novartis has received approval from the US Food and Drug Administration (FDA) for its Kisqali (ribociclib) in combination with an aromatase inhibitor as the first-line treatment of advanced or metastatic breast cancer.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | HER2 | Pharmaceuticals